You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博瑞醫藥(688166.SH)擬投建海外高端製劑藥品生產項目
格隆匯 12-09 18:38

格隆匯12月9日丨博瑞醫藥(688166.SH)公佈,公司為建設符合美國、歐盟cGMP標準的注射劑生產製造基地擬投資建設海外高端製劑藥品生產項目,該項目總投資約3.48億元人民幣,擬通過自有資金以及向銀行項目貸款方式實施,其中銀行貸款不超過2.5億元。項目建設期為2年,實施主體為博瑞生物醫藥(蘇州)股份有限公司,項目的建設地點位於蘇州工業園區。

公司目前形成了高技術附加值的醫藥中間體和原料藥銷售、藥品技術轉讓以及利用自身技術和產品優勢與其它具有品牌或銷售渠道優勢的醫藥企業合作開發並獲得銷售分成等多元化的盈利模式,並進一步向製劑產品領域拓展,逐步建立起原料藥與製劑一體,仿製藥與創新藥結合,國際市場與國內市場並重的業務體系。

根據公司的發展戰略,在仿製藥領域,公司將繼續深耕高端仿製藥市場,持續提升產品技術研發、法規註冊、知識產權、GMP生產、全球商業化及綜合管理能力,構建平台型高端化學制藥企業。公司將圍繞自身核心技術能力,一方面繼續向製劑產品領域拓展,另一方面繼續拓展國際市場。

項目的實施,將保證公司高端注射劑產品擁有符合美國、歐盟cGMP準的生產製造能力,是公司發展戰略的真實實踐。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account